Developing Treatments for Food Allergies Using Standardized, Pharmaceutical-Grade Food Allergens and Characterized Oral Desensitization Immunotherapy
Learn More About Aimmune
Highly selective medicines for genomically defined cancers.
Aisling congratulates the management team of Loxo on its recent acquisition by Eli Lilly.
Learn More About Loxo
Developing late-stage neuroscience compounds targeting migraine and psychiatric disorders.
Learn More About Biohaven
Novel treatments for people living with narcolepsy and other central nervous system disorders.
learn moreLearn More About Harmony Biosciences
CoolSculpting®: more science, less fat.
Aisling congratulates the management team of Zeltiq on its recent acquisition by Allergan.
Learn More About Zeltiq
Largest provider of biopharmaceutical development and commercial outsourcing services.
Learn More About QuintilesAisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.
See Our Portfolio
$1.8 billion in assets, with a track record of investing and returning capital since 2000.
learn moreLatest News
Elevation Oncology Announces Pricing of Initial Public Offering
June 24, 2021
NEW YORK, NY – June 24, 2021 – Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers,…
READ MORE
Monte Rosa Therapeutics Announces Pricing of Initial Public Offering
June 23, 2021
Boston, MA – June 23, 2021 – Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing a portfolio of novel small molecule precision medicines that employ the body’s natural…
READ MORE
Talaris Therapeutics Announces Closing of Initial Public Offering
May 11, 2021
BOSTON and LOUISVILLE, KY - May 11, 2021 - Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of…
READ MORE